Abstracts tagged "T Cell"

Abstract Number: 0874 • ACR Convergence 2024
Defining a Protective Role for Mucosal-associated Invariant T (MAIT) Cells in Spontaneous Cutaneous Lupus Erythematosus
Grace Crossland¹, Lindsay Mendyka², Michael Constantinides³ and Sladjana Skopelja-Gardner¹, ¹Dartmouth Geisel School of Medicine, Lebanon, NH, ²Dartmouth Hitchcock Memorial Hospital, Lyme, NH, ³Scripps Research Institute, San Diego, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a leading cause of death in young females, and 70-85% of patients experience skin disease (cutaneous LE, CLE). The…
Abstract Number: 1661 • ACR Convergence 2024
Rheumatoid Arthritis Synovial Fibroblast Modulation of T Cell Activation
Melissa Romoff¹, Daniel Ramirez², Edward Dicarlo³, Susan Goodman⁴, Alexander Rudenska⁵, Laura Donlin¹ and Melanie Smith¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Cartago, Costa Rica, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, New York 10025, NY, ⁵Memorial Sloan Kettering Cancer Center, New York, NY
Background/Purpose: In the rheumatoid arthritis (RA) joint, resident synovial fibroblasts (FLS) interact with infiltrating leukocytes. We previously identified a population of sublining FLS responsive to…
Abstract Number: 1840 • ACR Convergence 2024
Synovial Resident Memory T Cell Formation During Inflammation Requires Cell Contact with Fibroblast-Like Synoviocytes
Yusuke Miyashita¹, Yang Yang¹, Madison Mangin¹, Maryrose Hahn², Kevin Wei³, Peter Nigrovic⁴ and Margaret Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Georgetown, MA, ³Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁴Boston Children's Hospital, Brookline, MA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by recurrent inflammation in the same joints, a feature termed joint-specific memory. We previously demonstrated…
Abstract Number: 1858 • ACR Convergence 2024
Co-modification of Citrullinated Proteins with Malondialdehyde-Acetaldehyde Leads to Amplified T Cell Responses and Increased Disease-specific Autoantibody Concentrations
Breanna Butler¹, Wenxian Zhou², Michael Duryee¹, Nozima Aripova¹, Engle Sharp¹, Carlos Hunter¹, Bridget Kramer¹, Harlan Sayles¹, James O'Dell¹, Geoffrey Thiele¹, Bryant England¹, Joshua Baker³, Andreas Reimold⁴, Gail Kerr⁵ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE, ³University of Pennsylvania, Philadelphia, PA, ⁴Dallas VA Medical Center, Dallas, TX, ⁵Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: Anti-citrullinated protein antibody (ACPA) is highly specific to rheumatoid arthritis (RA). Beyond citrullination, other post-translational protein modifications including malondialdehyde-acetaldehyde (MAA) are targeted by T…
Abstract Number: 2427 • ACR Convergence 2024
Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Induces Multicompartmental B Cell Depletion in Peripheral Blood, Bone Marrow and Lymph Nodes of Systemic Lupus Erythematosus
Ioanna Minopoulou¹, Olaf Penack², Fredrik Albach¹, Artur Wilhelm³, Arnd Kleyer⁴, Dominic Borie⁵, Vincent Casteleyn¹, Robert Biesen¹, Philipp Enghard⁶, Thomas Dörner⁷, Norman Drzeniek⁸, Jan Zernicke¹, Tobias Alexander³, Kamran Movassaghi², Marie Luise Hütter-Krönke⁹, Eva Schrezenmeier⁶, Adrian Schreiber¹⁰, udo schneider¹, Lars Bullinger¹¹, Gerhard Krönke¹² and David Simon¹³, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ²Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany/ Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Berlin, Germany, ⁵Kyverna Therapeutics, Inc., Emeryville, CA, ⁶Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin, Berlin, Germany/ Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁷Department of Medicine, Rheumatology and Clinical Immunology,Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ⁸Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Berlin Institute of Health at Charité-Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany/ Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Berlin-Brandenburg School for Regenerative Therapies (BSRT), Berlin, Germany/Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical Immunology, Berlin, Germany, Berlin, Germany, ⁹Department of Hematology, Oncology and Cancer Immunology, Charité University Medicine Berlin, Campus Steglitz, Berlin, Germany, Berlin, Germany, ¹⁰Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin, Berlin, Germany, Berlin, Germany, ¹¹Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany/ Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany, Berlin, Germany, ¹²Rheumatology, Charité, Berlin, Germany, ¹³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany/Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Berlin, Germany
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cells have emerged as a promising therapeutic option for treatment-refractory patients with B cell-mediated diseases such as systemic…
Abstract Number: 0080 • ACR Convergence 2024
Enhanced Cytotoxicity of Aging Associated NKG2C+ CD8+ T Cells in Ankylosing Spondylitis via HLA-B27
Kunhai Tang, Xiaobei Ma, Jian Gao, Feng Qian, Qi Zhu, Jiucun Wang and Jing Liu, Fudan University, Shanghai, China (People's Republic)
Background/Purpose: Ankylosing spondylitis (AS) is an immune-related chronic inflammatory disease characterized by inflammatory pain in the lower back and spinal ankylosing, accompanied by immune system disorders, such…
Abstract Number: 0876 • ACR Convergence 2024
C-CAR168 as a Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy for the Treatment of Autoimmune Diseases
jiaqi Huang¹, Xin Yao¹, Xiaobing Luo¹, Xiaoteng Lv², Yutian Wei², Michael Patrick¹, Fei Wang², Yi Hong² and Yihong Yao¹, ¹AbelZeta Inc., Rockville, MD, ²AbelZeta Inc., Shanghai, China (People's Republic)
Background/Purpose: B cells are pivotal in autoimmune disease pathogenesis as they produce autoantibodies and undergo aberrant maturation processes, and B-cell dysregulation and the production of…
Abstract Number: 1707 • ACR Convergence 2024
TRBV9-Targeted Bispecific T Cell-Engaging Antibodies to Reset the Autoreactive T Cell Compartment in Spondyloarthritis and HLA-DQ8 Celiac Disease
Stephanie Glavaris, Alexander Pearlman, Jin Liu, Jiaxin Ge, Yuanxuan Xia, Kyle J. Kaeo, Tolulope Awosika, Colin Gliech, Tushar Nichakawade, Nikita Marcou, Chetan Bettegowda, Drew Pardoll, Kenneth W. Kinzler, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Therapies that indiscriminately deplete all T cells carry a high risk of opportunistic infection, precluding their widespread use in T cell-mediated autoimmune diseases. Targeting…
Abstract Number: 1841 • ACR Convergence 2024
Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases
Kristen Zhang, Joanne Li, Duy Nguyen, Nguyen Tan, Hsin-Yuan Cheng, David Huang, Suhasni Gopalakrishnan, Zachary Roberts, Cesar Sommer and Elvin Lauron, Allogene Therapeutics, South San Francisco, CA
Background/Purpose: Autologous CD19 chimeric antigen receptor (CAR) T cell therapies have recently shown to be well tolerated and highly effective in patients with autoimmune diseases…
Abstract Number: 1859 • ACR Convergence 2024
Clonal Relationships Between Tph and Tfh Cells in Patients with SLE and in Murine Lupus
Takanori Sasaki¹, John Sowerby², Yinan Xiao², Runci Wang², Pui Lee³, Yujie Qu⁴, Marc Sze⁴, Stephen Alves⁴, Marc Levesque⁴, Karen Costenbader⁵ and Deepak Rao⁶, ¹Brigham and Women's Hospital and Harvard Medical School, Brookline, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Boston Children's Hospital, Newton, MA, ⁴Merck & Co., Inc., Boston, MA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: T helper cells, including T peripheral helper (Tph) cells and T follicular helper (Tfh) cells, play pivotal roles in promoting B cell activation and…
Abstract Number: 2430 • ACR Convergence 2024
Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a Phase 2b Trial
Alex S. Powlesland¹, Ioana Cutcutache¹, Andrew Skelton¹, Anthony Shock¹, Matthew Page¹, Eris Bame², Janine Gaiha-Rohrbach², George Stojan³, Ania Skowera¹, Christian Stach⁴ and Thomas Dörner⁵, ¹UCB Pharma, Slough, United Kingdom, ²Biogen Inc., Cambridge, MA, ³UCB Pharma, Atlanta, GA, ⁴UCB Pharma, Monheim am Rheim, Germany, ⁵Department of Medicine, Rheumatology and Clinical Immunology,Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany
Background/Purpose: CD40-CD40L interactions play a pivotal role in systemic lupus erythematosus (SLE) pathogenesis by orchestrating a range of immune and inflammatory responses involving B cells,…
Abstract Number: 0087 • ACR Convergence 2024
SYNCAR: An Engineered IL-2/IL-2R-system That Selectively Enhances CD19 CAR T Cells to Deplete B Cells and Provide Therapeutic Benefit in SLE and RA Mouse Models Without Lymphodepletion
Ethan Jung¹, Marie semana¹, Ivan Cheng¹, Helena Silva¹, Sandro Vivona¹, Somya Singh¹, Michele Bauer¹, Mohammed Ali¹, Henry Rosas¹, Woei Chang¹, Deepti Rokkam¹, Patrick Lupardus¹, Martin Oft¹ and Paul-Joseph Aspuria², ¹Synthekine, Menlo Park, ²Sythekine, Menlo Park, CA
Background/Purpose: CD19 CAR-T therapy has demonstrated efficacy in autoimmune (AI) diseases like systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing its potential beyond oncology.…
Abstract Number: 0885 • ACR Convergence 2024
Reproducible Single Cell Annotation of Programs Underlying T-cell Subsets, Activation States, and Functions
Dylan Kotliar¹, Michelle Curtis¹, Ryan Agnew¹, Kathryn Weinand¹, Aparna Nathan², Yuriy Baglaenko¹, Yu Zhao¹, Pardis Sabeti³, Deepak Rao⁴ and Soumya Raychaudhuri¹, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Broad Institute, Boston, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Background/Purpose: T-cells play a key role in the pathogenesis of autoimmune disease and in protection against cancer and infection. Consequently, there is widespread interest in…
Abstract Number: 1751 • ACR Convergence 2024
Precision Targeting of Autoreactive 9G4 B Cells in Systemic Lupus Erythematosus Using Engineered Chimeric Antigen Receptor (CAR)- and Chimeric T Cell Receptor (cTCR)-T Cells
Jin Liu¹, Brian Mog¹, Yuanxuan Xia¹, Elana Shaw¹, Alexander Pearlman¹, Dylan Ferris¹, Kyle J. Kaeo¹, Colin Gliech¹, Tolulope Awosika¹, Brock Moritz¹, Tushar Nichakawade¹, Yang Li¹, Stephanie Glavaris¹, Sarah DiNapoli¹, Nikita Marcou¹, Taha Ahmedna¹, Victoria Duarte Alvarado¹, Denis Wirtz¹, Regina Bugrovsky², Scott A. Jenks², Iñaki Sanz³, Daniel Goldman⁴, Michelle Petri⁴, Chetan Bettegowda¹, Suman Paul¹, Kenneth W. Kinzler¹, Shibin Zhou¹, Felipe Andrade⁵, Bert Vogelstein¹ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Emory University School of Medicine, Atlanta, GA, ³Emory University School of Medicine, Atlanta, ⁴Johns Hopkins University School of Medicine, Timonium, MD, ⁵The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: The autoreactive B cell compartment in systemic lupus erythematosus (SLE) is characterized by expansion of B cells expressing immunoglobulin heavy variable gene 4-34 (IGHV4-34)…
Abstract Number: 1842 • ACR Convergence 2024
Development of Next Generation CAR T Cell Therapy for the Off-the-shelf Treatment of Autoimmune Diseases Without Conditioning Chemotherapy
John Goulding¹, John Reiser², Alison O'Connor¹, Bryan Hancock¹, Jonatan Tuncel¹, Brian Groff¹, Rina Mbofung¹, Daniel Morales-Mantilla¹, Allan Williams¹, Dan Lu¹, Bi-Huei Yang¹, Eigen Peralta¹, Alma Gutierrez¹, Miguel Meza¹, Betsy Rezner¹, Amanda Sims¹, Alec Witty¹, Yijia Pan¹, Mark Jelcic¹, Shohreh Sikaroodi¹, Matthew Denholtz¹, Tom Lee¹, Anil Bagri¹, Lilly Wong¹, Jode Goodridge¹ and Bahram Valamehr¹, ¹Fate Therapeutics Inc., San Diego, CA, ²Fate Therapeutics Inc, San Diego, CA
Background/Purpose: Developed initially as a novel strategy to treat B cell malignancies, chimeric antigen receptor (CAR) T cells have now been used to treat multiple…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].